(Q40126702)

17 September 2017

Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies (English)

1 reference

17 September 2017

1 reference

Tino Schenk

1

1 reference

17 September 2017

Sven Stengel

2

1 reference

17 September 2017

Stefanie Goellner

3

1 reference

17 September 2017

Daniel Steinbach

4

1 reference

17 September 2017

Hans Peter Saluz

5

1 reference

17 September 2017

1 September 2007

1 reference

Genes, Chromosomes and Cancer

17 September 2017

1 reference

17 September 2017

46

1 reference

17 September 2017

9

1 reference

17 September 2017

796-804

1 reference

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

17 September 2017

1 reference

Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR.

21 January 2018

1 reference

7 January 2021

Methylation-induced repression--belts, braces, and chromatin

1 reference

7 January 2021

Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes

1 reference

7 January 2021

MAGE-A genes are not expressed in human leukemias

1 reference

7 January 2021

Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells

1 reference

7 January 2021

Promoter inhibition by DNA methylation: a reversible signal

1 reference

7 January 2021

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling

1 reference

7 January 2021

A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands

1 reference

7 January 2021

Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression

1 reference

7 January 2021

Simultaneous expression of different immunogenic antigens in acute myeloid leukemia

1 reference

7 January 2021

Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.

1 reference

7 January 2021

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

1 reference

7 January 2021

Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia

1 reference

7 January 2021

Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.

1 reference

7 January 2021

Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation

1 reference

7 January 2021

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome

1 reference

7 January 2021

PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects

1 reference

7 January 2021

A new mathematical model for relative quantification in real-time RT-PCR

1 reference

7 January 2021

Gene expression changes associated with progression and response in chronic myeloid leukemia

1 reference

7 January 2021

CpG methylation, chromatin structure and gene silencing-a three-way connection

1 reference

7 January 2021

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

1 reference

7 January 2021

Clinical implications of PRAME gene expression in childhood acute myeloid leukemia

1 reference

7 January 2021

PRAME gene expression in childhood acute lymphoblastic leukemia

1 reference

7 January 2021

Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia

1 reference

7 January 2021

Towards a pharmacology of DNA methylation

1 reference

7 January 2021

PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells

1 reference

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

7 January 2021

Identifiers

DOI

10.1002/GCC.20465

1 reference

17 September 2017

1 reference